Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced for quarter ended March 31, 2026.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for quarter ended March 31, 2026
- Detailed results and management commentary contained in Exhibit 99.1 press release
- Disclosure furnished under Regulation FD, limiting Section 18 liability and automatic incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 collaboration revenue $34.4M, up from $22.1M, reflecting Gilead-linked activity
- Gilead’s KT-200 license option generated a $45M milestone, expected in Q2 2026; IND planned for 2027
- KT-621 Phase 2b trials target approximately 200 AD patients and 264 asthma patients, with data expected mid-2027 and late 2027
- FDA Fast Track designation expanded KT-621’s regulatory support to moderate-to-severe eosinophilic asthma
- Cash, equivalents and investments $1.55B at March 31, supporting runway into 2029 despite Q1 net loss of $69.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.